Christine M Burns1,2, David S Knopman3, David E Tupper2,4, Cynthia S Davey5, Yelena M Slinin6,7, Kamakshi Lakshminarayan2,8, Rebecca C Rossom9, Sarah L Pederson1, David T Gilbertson10, Anne M Murray1,7,11. 1. Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minnesota. 2. Department of Neurology, University of Minnesota, Minneapolis. 3. Department of Neurology, Mayo Clinic, Rochester, Minnesota. 4. Department of Psychology and Neuropsychology, Hennepin County Medical Center, Minneapolis, Minnesota. 5. Biostatistical Design and Analysis Center, University of Minnesota Clinical and Translational Science Institute, Minneapolis. 6. Minneapolis VA Health Care Center, Minnesota. 7. Department of Medicine, University of Minnesota, Minneapolis. 8. Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis. 9. HealthPartners Institute, Bloomington, Minnesota. 10. Chronic Disease Research Group, Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minnesota. 11. Geriatrics Division, Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota.
Abstract
Background: Our primary goal is to describe the prevalence, severity, and risk of cognitive impairment (CI) by estimated glomerular filtration rate (eGFR, in mL/min/1.73 m2) in a cohort enriched for advanced chronic kidney disease (CKD; eGFR < 45), adjusting for albuminuria, as measured by urine albumin-to-creatinine ratio (UACR, in mg/g). As both eGFR and albuminuria are associated with CI risk in CKD, we also seek to determine the extent that eGFR remains a useful biomarker for risk of CI in those with CKD and concomitant albuminuria. Methods: Chi-square tests measured the prevalence of severe CI and mild cognitive impairment (MCI) by eGFR level. Logistic regression models and generalized linear models measured risk of CI by eGFR, adjusted for UACR. Results: Participants were 574 adults with a mean age of 69; 433 with CKD (eGFR < 60, nondialysis) and 141 controls (eGFR ≥ 60). Forty-eight percent of participants with CKD had severe CI or MCI. The prevalence of severe CI was highest (25%) in those with eGFR < 30. eGFR < 30 was only associated with severe CI in those without albuminuria (UACR < 30; OR = 3.3; p = .02) and was not associated with MCI in similar models. Conclusions: One quarter of those with eGFR < 30 had severe CI. eGFR < 30 was associated with over threefold increased odds of severe CI in those with UACR < 30, but not with UACR > 30, suggesting that eGFR < 30 is a valid biomarker for increased risk of severe CI in those without concomitant albuminuria.
Background: Our primary goal is to describe the prevalence, severity, and risk of cognitive impairment (CI) by estimated glomerular filtration rate (eGFR, in mL/min/1.73 m2) in a cohort enriched for advanced chronic kidney disease (CKD; eGFR < 45), adjusting for albuminuria, as measured by urine albumin-to-creatinine ratio (UACR, in mg/g). As both eGFR and albuminuria are associated with CI risk in CKD, we also seek to determine the extent that eGFR remains a useful biomarker for risk of CI in those with CKD and concomitant albuminuria. Methods: Chi-square tests measured the prevalence of severe CI and mild cognitive impairment (MCI) by eGFR level. Logistic regression models and generalized linear models measured risk of CI by eGFR, adjusted for UACR. Results:Participants were 574 adults with a mean age of 69; 433 with CKD (eGFR < 60, nondialysis) and 141 controls (eGFR ≥ 60). Forty-eight percent of participants with CKD had severe CI or MCI. The prevalence of severe CI was highest (25%) in those with eGFR < 30. eGFR < 30 was only associated with severe CI in those without albuminuria (UACR < 30; OR = 3.3; p = .02) and was not associated with MCI in similar models. Conclusions: One quarter of those with eGFR < 30 had severe CI. eGFR < 30 was associated with over threefold increased odds of severe CI in those with UACR < 30, but not with UACR > 30, suggesting that eGFR < 30 is a valid biomarker for increased risk of severe CI in those without concomitant albuminuria.
Authors: Kristine Yaffe; Lynn Ackerson; Manjula Kurella Tamura; Patti Le Blanc; John W Kusek; Ashwini R Sehgal; Debbie Cohen; Cheryl Anderson; Lawrence Appel; Karen Desalvo; Akinlolu Ojo; Stephen Seliger; Nancy Robinson; Gail Makos; Alan S Go Journal: J Am Geriatr Soc Date: 2010-01-26 Impact factor: 5.562
Authors: Adam Davey; Merrill F Elias; Michael A Robbins; Stephen L Seliger; Gregory A Dore Journal: Nephrol Dial Transplant Date: 2012-11-18 Impact factor: 5.992
Authors: Prashanthi Vemuri; David S Knopman; Clifford R Jack; Emily S Lundt; Stephen D Weigand; Samantha M Zuk; Kaely B Thostenson; Robert I Reid; Kejal Kantarci; Yelena Slinin; Kamakshi Lakshminarayan; Cynthia S Davey; Anne Murray Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Manjula Kurella; Kristine Yaffe; Michael G Shlipak; Nanette K Wenger; Glenn M Chertow Journal: Am J Kidney Dis Date: 2005-01 Impact factor: 8.860
Authors: Manjula Kurella Tamura; Virginia Wadley; Kristine Yaffe; Leslie A McClure; George Howard; Rodney Go; Richard M Allman; David G Warnock; William McClellan Journal: Am J Kidney Dis Date: 2008-06-30 Impact factor: 8.860
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Anne M Murray; Le Thi Phuong Thao; Joanne Ryan; Rory Wolfe; James B Wetmore; Robyn L Woods; Kevan R Polkinghorne Journal: Kidney360 Date: 2021-12-07
Authors: Jeremy A Syrjanen; Michelle R Campbell; Alicia Algeciras-Schimnich; Prashanthi Vemuri; Jonathan Graff-Radford; Mary M Machulda; Guojun Bu; David S Knopman; Clifford R Jack; Ronald C Petersen; Michelle M Mielke Journal: Alzheimers Dement Date: 2021-09-27 Impact factor: 16.655
Authors: Yun Fei Wang; Li Juan Zheng; Ya Liu; Yu Bing Ye; Song Luo; Guang Ming Lu; Dehua Gong; Long Jiang Zhang Journal: Theranostics Date: 2019-10-18 Impact factor: 11.556